search
Back to results

GUM Hydral Mouthwash vs Placebo in the Management of Hyposalivation.

Primary Purpose

Xerostomia, Xerostomia Following Radiotherapy

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Hydral
Placebo
Sponsored by
Catholic University of the Sacred Heart
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Xerostomia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients willing to sign the informed consent form
  • Patients older than 18 years
  • Patients with diagnosis of HNC, who had received local radiotherapy at least three months before the beginning of the study, involving the salivary glands, both for curative and palliative purpose, with or without chemotherapic treatment, reporting xerostomia symptoms
  • Patients with diagnosis of HNC, who had received local radiotherapy as an adjuvant to surgical resection at least three months before the beginning of the study, with or without chemotherapic treatment, reporting xerostomia symptoms-

Exclusion Criteria:

  • Patients with documented contraindication to any of the components of GUM HYDRAL (there included eccipients)
  • Patients with any neurological and psychiatric condition having an influence on the ability to self-apply the treatment
  • Patients unwilling to complete the request diary card
  • Patients unable to attend the ambulatory visits scheduled by the protocol
  • Patients participating to other clinical studies
  • Patients who had received antitumoral treatment during the previous three months
  • Patients with concomitant Sjogren's syndrome
  • Other causes of xerostomia (pharmacological treatment)

Sites / Locations

  • Catholic University of the Sacred Hearth

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Hydral

Placebo

Arm Description

The participants will be asked to rinse their mouth five times a day with the experimental product. After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)

The participants will be asked to rinse their mouth five times a day with the placebo comparator. After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)

Outcomes

Primary Outcome Measures

Improvement of the Xerostomia Questionnaire (XQ)
The modified XQ provides a measure of the severity of radiation -induced xerostomia that affects the patients' QoL. This questionnaire consists of 10 questions, associated with patient-reported dryness. Moreover, a general question "how dry is your mouth?" has been added to the questionnaire. The modified XQ is a self-administered tool and patients will be asked to rate each symptom on a 10-point NRS scale of 0-10, with higher scores indicating more severe dryness or discomfort due to dryness. Each item score is added, and the sum is linearly transformed to produce the final summary score ranging from 0 to 100, with higher scores representing higher levels of xerostomia.

Secondary Outcome Measures

Improvement of the EORTC QLQ-30 questionnaire
The QLQ-C30 provides 30 questions, globally assessing patients' quality of life. The answers will be converted into a linear scoring scale, with values between 0 and 100, as advocated by EORTC.
Improvement of the EORTC QLQ_H&N-35 Questionnaire
The QLQ-H&N35 includes 35 questions, and addresses symptoms associated with specific tumor location, side effects associated with the oncologic treatment and additional QoL aspects modified by the disease or its treatment. The answers will be converted into a linear scoring scale, with values between 0 and 100, as advocated by EORTC.

Full Information

First Posted
October 17, 2021
Last Updated
July 26, 2022
Sponsor
Catholic University of the Sacred Heart
Collaborators
Sunstar Italiana SRL.
search

1. Study Identification

Unique Protocol Identification Number
NCT05103124
Brief Title
GUM Hydral Mouthwash vs Placebo in the Management of Hyposalivation.
Official Title
Efficacy of GUM Hydral Mouthwashes on Symptoms of Radiotherapy-induced Xerostomia: a Randomized, Double-blind, Crossover Study.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
November 3, 2020 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
July 26, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Catholic University of the Sacred Heart
Collaborators
Sunstar Italiana SRL.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
There is currently little robust evidence to inform the management of hyposalivation and xerostomia in this population. Although the treatment of xerostomia is very individual, a first-line medication is needed to ameliorate the dehydration in the mouth by substituting for the secretion of saliva. The aim of this study is to describe the effect of the administration of Hydral on reducing patients' xerostomia symptoms due to radiotherapy. The study will be conducted as a double-blind randomized clinical trial (RCT) and foresees a crossover design, so the population will be divided into two groups, receiving both the medical device and the placebo.
Detailed Description
Head and neck squamous cell carcinoma (HNSCC) accounts for more than 750,000 new cases per year and its prognosis is still poor in terms of mortality and of morbidity and it causes approximately 350,000 deaths annually worldwide. Radiotherapy (RT) is an established treatment modality for HNSCC and other H&N tumors, either for treatment alone or as adjuvant. Unfortunately, high-dose RT has significant adverse effects on the oral and maxillofacial tissues, both hard and soft. In particular, when salivary glands are within the irradiated field, irreversible salivary glands damage occurs in 63-93% of the patients. Salivary gland damage typically manifests as reduced saliva secretion, which in turn can translate into a subjective sensation of dry mouth (xerostomia), oral discomfort, altered taste, difficulty with speaking, swallowing, chewing, and increased risk of dental disease. Overall hyposalivation and related xerostomia can cause a substantial reduction in quality-of-life (QoL). However there is currently little robust evidence to inform the management of hyposalivation and xerostomia in this population. Although the treatment of xerostomia is very individual, a first-line medication is needed to ameliorate the dehydration in the mouth by substituting for the secretion of saliva. GUM Hydral (GUM Hydral: Sunstar Italiana SRL. Corso Italia 13 21047 Saronno, VA, Italy) is a product based on hyaluronic acid and sodium citrate. It helps in rehydrating and protecting the oral tissues, by forming a film on those tissues. It may be helpful in reducing the xerostomia symptoms. The device is a high-density liquid and it is used as a mouthwash. In this trial, the aim is to investigate if its efficacy in reducing the xerostomia symptoms is higher than placebo. The placebo will be made of water with xylitol in addition. Xylitol is a is a sugar alcohol used as a sugar substitute, which does not increase the risk of tooth decay. In this formulation, its only role is to give a slight sweet flavor to water. The aim of this study is to describe the effect of the administration of Hydral on reducing patients' xerostomia symptoms due to radiotherapy. The study will be conducted as a double-blind randomized clinical trial (RCT) and foresees a crossover design, so the population will be divided into two groups, receiving both the medical device and the placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Xerostomia, Xerostomia Following Radiotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hydral
Arm Type
Experimental
Arm Description
The participants will be asked to rinse their mouth five times a day with the experimental product. After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The participants will be asked to rinse their mouth five times a day with the placebo comparator. After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)
Intervention Type
Device
Intervention Name(s)
Hydral
Intervention Description
The investigational product GUM Hydral will be administered for a 30-days treatment period
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
The placebo product will be administered for a 30-days treatment period
Primary Outcome Measure Information:
Title
Improvement of the Xerostomia Questionnaire (XQ)
Description
The modified XQ provides a measure of the severity of radiation -induced xerostomia that affects the patients' QoL. This questionnaire consists of 10 questions, associated with patient-reported dryness. Moreover, a general question "how dry is your mouth?" has been added to the questionnaire. The modified XQ is a self-administered tool and patients will be asked to rate each symptom on a 10-point NRS scale of 0-10, with higher scores indicating more severe dryness or discomfort due to dryness. Each item score is added, and the sum is linearly transformed to produce the final summary score ranging from 0 to 100, with higher scores representing higher levels of xerostomia.
Time Frame
After a one-month therapy both with Hydral and Placebo
Secondary Outcome Measure Information:
Title
Improvement of the EORTC QLQ-30 questionnaire
Description
The QLQ-C30 provides 30 questions, globally assessing patients' quality of life. The answers will be converted into a linear scoring scale, with values between 0 and 100, as advocated by EORTC.
Time Frame
After a one-month therapy both with Hydral and Placebo
Title
Improvement of the EORTC QLQ_H&N-35 Questionnaire
Description
The QLQ-H&N35 includes 35 questions, and addresses symptoms associated with specific tumor location, side effects associated with the oncologic treatment and additional QoL aspects modified by the disease or its treatment. The answers will be converted into a linear scoring scale, with values between 0 and 100, as advocated by EORTC.
Time Frame
After a one-month therapy both with Hydral and Placebo

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients willing to sign the informed consent form Patients older than 18 years Patients with diagnosis of HNC, who had received local radiotherapy at least three months before the beginning of the study, involving the salivary glands, both for curative and palliative purpose, with or without chemotherapic treatment, reporting xerostomia symptoms Patients with diagnosis of HNC, who had received local radiotherapy as an adjuvant to surgical resection at least three months before the beginning of the study, with or without chemotherapic treatment, reporting xerostomia symptoms- Exclusion Criteria: Patients with documented contraindication to any of the components of GUM HYDRAL (there included eccipients) Patients with any neurological and psychiatric condition having an influence on the ability to self-apply the treatment Patients unwilling to complete the request diary card Patients unable to attend the ambulatory visits scheduled by the protocol Patients participating to other clinical studies Patients who had received antitumoral treatment during the previous three months Patients with concomitant Sjogren's syndrome Other causes of xerostomia (pharmacological treatment)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlo Lajolo, Prof.
Organizational Affiliation
CU Sacred Hearth
Official's Role
Principal Investigator
Facility Information:
Facility Name
Catholic University of the Sacred Hearth
City
Roma
ZIP/Postal Code
00168
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

GUM Hydral Mouthwash vs Placebo in the Management of Hyposalivation.

We'll reach out to this number within 24 hrs